Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.48 |
| ▸ | PSMB1 | P20618 | 6/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.42 |
| ▸ | PSMB2 | P49721 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylamine SCHEMBL1583273 | 0.93 | HRH3 (0.42) | HRH3PSMB1PSMB5PSMB2ALDH1A1 | |
| SCHEMBL14041546 | 0.85 | HRH3 (0.56) | HRH3 | |
| SCHEMBL14553250 | 0.83 | HRH3 (0.61) | HRH3L3MBTL1 | |
| SCHEMBL8159902 | 0.82 | HRH3 (0.52) | HRH3ALDH1A1 | |
| SCHEMBL22310345 | 0.80 | HRH3 (0.56) | HRH3ALDH1A1MAPTL3MBTL1 | |
| Methylamine SCHEMBL1582949 | 0.80 | HRH3 (0.50) | HRH3ALDH1A1L3MBTL1 | |
| SCHEMBL24059343 | 0.78 | HRH3 (0.60) | HRH3PSMB1PSMB5PSMB2NPC1 | |
| SCHEMBL8361918 | 0.78 | HRH3 (0.60) | HRH3PSMB1PSMB5PSMB2NPC1 | |
| SCHEMBL7887990 | 0.78 | HRH3 (0.60) | HRH3PSMB1PSMB5PSMB2NPC1 | |
| SCHEMBL21386592 | 0.77 | ALDH1A1 (0.40) | HRH3NPC1ALDH1A1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021195599-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-20200038513-A1 | MODULATORS OF FAK PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
| WO-2007118137-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038513-A1 | MODULATORS OF FAK PROTEOLYSIS AND ASSOCIATED METHODS OF USE | PTK2, CTTN, CRBN | HRH3 3687/4885PSMB1 252/4885PSMB5 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.